Quote:

---

Rough calculation

Start with 100 mCRC patients:
Heavily pretreated: ~65
MSS only: 85% → ~55
CCR5-positive: ~35% → ~19
ECOG 0–1 + organ function: ~45% → ~9
Exclusions: lose ~15% → ~8

---

There are approximately 1,400,000 colorectal cancer patients in the U.S. so even if you go by the 8% ChatGPT comes up with that's up to 112, 000 patients for our trial.

But what is the basis of ChatGPT's percentages. Let's take a look at just one aspect of that to see where the whole thing falls apart. One study showed 80% of CRC tumors to have some CCR5 expression. Most others show above 50%. mssCRC shows higher levels than mCRC. The level also increases as the tumor grows. So that 30% is out the window.

Looking at it from the treatment perspective CCR5 on the main tumor is of importance. But even CCR5 expression in the tumor microenvironment has a lot of import when it comes disease progression. A point I've made before is that even non-localized CCR5 has effect. CCR5 enhancing metastasis to other sites and protecting those metastatic lesions. The increase in killer macrophages that originate in the bone marrow. Even CCR5 increasing mesenchymal stem cells in the bome marrow that are tumor protectant.